About 59% of adults with type 2 diabetes treated with tirzepatide shifted to a lower BMI category, and this shift was associated with broader cardiometabolic improvements.
58.9% improved BMI categoryAmong 3,559 adults with type 2 diabetes across five SURPASS trials, with associated improvements in cardiometabolic parameters and quality of life
What the researchers found
Across the pooled SURPASS-1 through -5 trial data (3,559 participants), 58.9% of tirzepatide-treated adults with type 2 diabetes shifted to an improved (lower) BMI category at weeks 40-52, while 41.1% remained in the same or a worsened category.
Participants who improved their BMI category showed numerically larger mean improvements from baseline in the majority of selected cardiometabolic parameters across all five trials compared to those who did not improve. Weight-related patient-reported outcomes were also numerically best in the improved BMI group, suggesting that meaningful BMI category shifts translate to both objective health improvements and subjective quality-of-life benefits.
Why it matters
BMI category changes are clinically meaningful benchmarks — moving from obesity class II to class I, or from obese to overweight, represents real thresholds that affect treatment guidelines, surgical eligibility, and disease risk. Showing that tirzepatide drives these category shifts in the majority of patients reinforces its potential to meaningfully change patients' health trajectories.
How the study worked
Post-hoc analysis of pooled data from SURPASS-1 through SURPASS-5, five Phase 3 randomized controlled trials of weekly tirzepatide in adults with type 2 diabetes. All tirzepatide doses were pooled. BMI changes were categorized as 'improved' (shift to one or more lower BMI categories) or 'not improved' (stable or worsened) from baseline to week 40 or 52. Associations with cardiometabolic parameters and weight-related patient-reported outcomes were assessed.
What this study cannot tell us
This is a post-hoc analysis, which means the trials were not originally designed to assess BMI category shifts as a primary endpoint. Improvements in cardiometabolic parameters were described as numerical (not always statistically significant) differences. The analysis pooled all tirzepatide doses, obscuring potential dose-response relationships. There was no placebo comparison in this specific BMI shift analysis.
How to read the evidence
This is a post-hoc analysis of Phase 3 randomized controlled trial data — the underlying trials are high quality, but this specific BMI category analysis was not a pre-specified endpoint, which somewhat reduces the evidence strength.
When this study was published
Published in 2025, this analysis draws on the SURPASS trial program that established tirzepatide as a major treatment option for type 2 diabetes and obesity.
The bigger picture
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has emerged as one of the most effective weight loss medications available. This analysis goes beyond average weight loss numbers to show that the majority of patients achieve clinically meaningful BMI category shifts — strengthening the case for tirzepatide as a transformative diabetes and obesity treatment.
Questions still open
- Do BMI category improvements persist after tirzepatide discontinuation?
- Which tirzepatide dose drives the greatest proportion of BMI category shifts?
- Are there baseline characteristics that predict which patients will achieve BMI category improvement?
Common questions
What does it mean to shift to a lower BMI category?
How does tirzepatide differ from other weight loss medications?
Read the original research
Improvement in body mass index category was associated with improved cardiometabolic measures and patient-reported outcomes in adults with type 2 diabetes treated with tirzepatide.
Diabetes, obesity & metabolism, 27(10), 5694-5705
Citation
Galindo, Rodolfo J; Lee, Clare J; Allen, Sheryl Elaine; Dib, Anne; Boye, Kristina S; Thieu, Vivian Thuyanh; Dong, Wenxiu; Sapin, Hélène; Wiese, Russell J. (2025). Improvement in body mass index category was associated with improved cardiometabolic measures and patient-reported outcomes in adults with type 2 diabetes treated with tirzepatide.. Diabetes, obesity & metabolism, 27(10), 5694-5705. https://doi.org/10.1111/dom.16620